Abstract

<div>Abstract<p><b>Purpose:</b> Identify and characterize novel combinations of sorafenib with anti-inflammatory painkillers to target difficult-to-treat <i>RAS</i>-mutant cancer.</p><p><b>Experimental Design:</b> The cytotoxicity of acetylsalicylic acid (aspirin) in combination with the multikinase inhibitor sorafenib (Nexavar) was assessed in <i>RAS</i>-mutant cell lines <i>in vitro</i>. The underlying mechanism for the increased cytotoxicity was investigated using selective inhibitors and shRNA-mediated gene knockdown. <i>In vitro</i> results were confirmed in <i>RAS</i>-mutant xenograft mouse models <i>in vivo</i>.</p><p><b>Results:</b> The addition of aspirin but not isobutylphenylpropanoic acid (ibruprofen) or celecoxib (Celebrex) significantly increased the <i>in vitro</i> cytotoxicity of sorafenib. Mechanistically, combined exposure resulted in increased BRAF/CRAF dimerization and the simultaneous hyperactivation of the AMPK and ERK pathways. Combining sorafenib with other AMPK activators, such as metformin or A769662, was not sufficient to decrease cell viability due to sole activation of the AMPK pathway. The cytotoxicity of sorafenib and aspirin was blocked by inhibition of the AMPK or ERK pathways through shRNA or via pharmacologic inhibitors of RAF (LY3009120), MEK (trametinib), or AMPK (compound C). The combination was found to be specific for <i>RAS/RAF</i>–mutant cells and had no significant effect in <i>RAS/RAF</i>–wild-type keratinocytes or melanoma cells. <i>In vivo</i> treatment of human xenografts in NSG mice with sorafenib and aspirin significantly reduced tumor volume compared with each single-agent treatment.</p><p><b>Conclusions:</b> Combination sorafenib and aspirin exerts cytotoxicity against <i>RAS/RAF</i>–mutant cells by simultaneously affecting two independent pathways and represents a promising novel strategy for the treatment of <i>RAS</i>-mutant cancers. <i>Clin Cancer Res; 24(5); 1090–102. ©2017 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.